March 21, 2024
Allergan Aesthetics Continues To Champion Individuality, Drive Innovation And Lead With Integrity As It Hosts Expert Led Symposia At AMWC 2024
  • Two expert-led Allergan Medical Institute (AMI) symposia will explore a personalized approach to aesthetics, featuring live injection sessions with Dr Mauricio De Maio, Dr Mansi Mukherjee and Dr Steven Liew
  • World class experts to convene on socially transformative aesthetic medicine at Science of AgingTM event
  • Seventeen posters exhibiting new clinical data on toxins and fillers showcase the diverse Allergan Aesthetics portfolio
  • Allergan Aesthetics' innovative discovery booth explores what it means to be a True Original

IRVINE, Calif., March 21, 2024 /PRNewswire/ -- Allergan Aesthetics demonstrates its ongoing commitment to originality and its bold approach to aesthetics at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from Wednesday, March 27– Friday, March 29, 2024. Events include two Allergan Medical Institute (AMI) symposia, Science of AgingTM event, Meet the Expert presentations, poster sessions and an interactive exhibition booth.

"AMWC presents an invaluable opportunity to meet with esteemed experts from across the globe," said Carrie Strom, President, Global Allergan Aesthetics. "Through our expert-led AMI symposia and series of thought-provoking events, we're showcasing our innovative approach to aesthetics with an emphasis on thoughtful consultation with our diverse and expanding product portfolio to further shape the future of the industry."

As industry pioneers, Allergan Aesthetics has been at the forefront of uncovering the trends that are shaping aesthetics. Activities taking place at AMWC this year further showcase Allergan Aesthetics timeless approach as it goes beyond the trends with decisive and thoughtful action. Centering around its True Originals theme, Individuality, Innovation and Integrity, Allergan Aesthetics is shaping the future of the aesthetics industry.

AMWC 2024 AMI symposia
The first symposium, 'True Originals: A Personalised Approach with the Allergan Aesthetics Range', focuses on an in-depth look into patient needs. The symposium will be co-chaired by Dr. Sophie Shotter (UK) and cosmetic dermatologist Dr. Andre Braz (Brazil), with expert panel discussions and two live injector sessions from Dr. Mansi Mukherjee (UAE) and Dr. Steven Liew (Australia).

The second day opens with an introduction to the future of individuality from Carrie Strom, President, Global Allergan Aesthetics, Dr. Tapan Patel (UK) and Dr. Juliana Chieppe (Brazil) and leads to the symposium 'True Originals: Decoding the Future of Aesthetic Individuality'. During the session, they will dive deeper into the exclusive report and discuss trends, techniques, and drivers for personalized treatment around the world. To end the day, renowned plastic surgeon Dr. Mauricio de Maio (Brazil) will perform a live injection on stage.

The symposia will take place as follows:

  • True Originals: A Personalised Approach with the Allergan Aesthetics Range. 11.15 AM1:15 PM on Wednesday, March 27 in the Salle des Princes, Grimaldi Forum
  • True Originals: Decoding the Future of Aesthetic Individuality. 9:45 AM– 12:45 PM on Thursday, March 28 in the Salle des Princes, Grimaldi Forum.

Beyond the AMI symposia
Dr. Steven Dayan will chair the Global Aesthetics Medical Affairs symposia, presenting 'Socially Transformative Aesthetic Medicine' alongside Dr. Mitchell Brin (US), Dr. Izolda Heydenrych (South Africa) and Damon Caiazza (US). Key topics include bias, emotional impact, social perception and future innovation.

Dr. Stephanie Manson Brown, Vice President, Head of Clinical Development and Scientific Innovation at Allergan Aesthetics, will open the exclusive thought-provoking Science of AgingTM symposia event, where world-class experts Dr Saranya Wyles (US), Professor Claire Stewart (UK), Professor Gordan Lauc (Croatia) and Dr Janine Sengstack (US) will present the latest early science and research insights in the field of aging. Key topics include cellular aging and rejuvenation, exosomes and glyconology. The session will conclude with a Q&A session led by event chair Dr. Patricia Ogilvie (Germany).

The symposia will take place as follows:

  • Global Aesthetics Medical Affairs Symposium. 2:00 PM4:00 PM on Wednesday, March 27 in the Genevoix Room, Grimaldi Forum
  • Science of AgingTM Symposium. 4:30 PM6:30 PM on Wednesday, March 27 in the Auric Room, Grimaldi Forum.

Meet the Experts
Allergan Aesthetics will host a series of Meet the Experts sessions live from the booth, featuring:

  • Combination treatment for male patients with Dr. Sebastien Derieux, France.
  • The importance of facial shape in Asian beauty with Dr. Jialun Li, China.
  • Juvéderm® VOLUMA® and VOLUX™ for the lower face – Drivers for Choice with Dr. Emily Schultz, Canada.
  • Combination treatment of Hyaluronic acid injection and Cryolipolysis for Lower face contouring with Dr. Kumiko Shimojima, Japan.
  • From Simple to Regal – Transformation with the Full Allergan Aesthetics Portfolio with Dr. Silvia Ramirez, Singapore.

AMWC 2024 marks the launch of Moving the Needle on Ethics, a collaboration with medical aesthetics experts from around the globe with the aim of igniting thoughtful conversations on the importance of ethics in aesthetics medicine. This initiative is a result of Allergan Aesthetics' extensive global research on ethics, which includes global social media listening, insight gathering and face-to-face discussions across the industry in 13 countries.1

Visit the global Allergan Aesthetics website to download the 'Moving the Needle on Ethics' book and discover how Allergan Aesthetics is spotlighting future industry priorities in collaboration with leading experts. The 'Moving the Needle on Ethics' short film will be available to watch from the booth.

Allergan Aesthetics booth
Attendees can explore interactive areas of the booth K2 (Ravel Floor) to learn more about Allergan Aesthetics' commitment to maintaining its True Original status, and actions it's taking to empower excellence and lead innovation in aesthetics.

New clinical data on toxins and fillers
Allergan Aesthetics' commitment to advancing clinical data and evidence is demonstrated with the acceptance of 17 poster presentations to this year's congress. Posters have been accepted across various products, treatments and indications. For poster details please see Notes to Editors below.

Be a True Original with Allergan Aesthetics. Visit the symposia and exhibition booth K2, Ravel Floor in the Grimaldi Forum to discover more.

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Notes to Editors
Please find titles and named authors for the 17 posters to be showcased at AMWC 2024 included below:

  1. OnabotulinumtoxinA Efficacy and Safety in the Treatment of Masseter Muscle Prominence: 6-Month Results From a Phase 3, Randomized, Placebo-Controlled, Multiregional Study. Authors: Jiaming Sun, Yan Wu, Shyi-Gen Chen, Shannon Humphrey, Steven Liew, Joan-En Chang-Lin, Lijuan Zhang, Grace Pan, Elisabeth Lee
  2. Patient-Reported Outcomes with Repeat Administration(s) of OnabotulinumtoxinA for the Treatment of Masseter Muscle Prominence: Results From a Phase 3 Multiregional Study. Authors: Shu-Hung Huang, William McGillivray, Yan Wu, Yuguang Zhan, Donna Faletto, Grace Pan, Catherine Foley, Vaishali Patel
  3. Patient-Reported Outcomes From OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Results From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial. Authors: Yuguang Zhang, William McGillivray, Shu Hung Huang, Donna Faletto, Grace Pan, Catherine Foley
  4. Treating Platysma Prominence with OnabotulinumtoxinA: Efficacy and Safety Results from a Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled Study. Authors: Sabrina Fabi, MD; Brian Biesman, MD, Rosalyn George, MD, Shannon Humphrey, MD, Brenda LaTowsky, MD; Robert Weiss, MD, Grace S. Park, DrPH, Warren Tong, PharmD, Elisabeth Lee, MBA, MPH, René Hopfinger, MS
  5. Safety and Efficacy of Multiple Simultaneous Cryolipolysis Treatments Using a Dual Applicator Cryolipolysis System. Authors: Amir Moradi, M.D.; Grant Stevens, M.D.; Felicia Tsai, MA; Rafael Ostrowski, BS; Sylvia Gamio, MSc; Eric Bachelor, M.D
  6. Towards a Mechanism of Action of Skin Changes after Cryolipolysis. Authors: Joel Jimenez Lozano, PhD
  7. Prospective, Multi-Country, Post-Marketing Study with Novel Dual-Applicator Cryolipolysis System Demonstrates High Participant Satisfaction, Safety and Effectiveness at 4 Weeks Post Initial Treatment and 12 Weeks Post Final Treatment Session. Authors: Jens Altmann, MD; Ulf Samuelson, MD; Sabrina Fabi, MD; Mitchel P. Goldman, MD; Suzanne Kilmer, MD; Jean Michel Mazer, MD; Roy Geronemus, MD; Terence Tan, MBBS, MRCS, MMed; Jordan Wang, MD, MBE, MBA; Yi Li; Alda Karic, PharmD
  8. A prospective, open-label, post-marketing study of the safety and effectiveness of HArmonyCa injectable gel for midface soft tissue augmentation: Interim analysis. Authors: Graeme Kerson, Alesandro Gritti, Malka Salomon, Andrew Schumacher
  9. Restoration of Jawline Definition in Males with Hyaluronic Acid Injectable Gel VYC-25L: Results from a Pivotal, Multicenter, Randomized Controlled Trial. Authors: Terrence Keaney, MD, FAAD; Raza Ahmed, MD; Elena Dimitrijevic, PhD; Alexander Rivkin, MD
  10. An Evaluation of VYC-17.5L for Forehead Contouring: A Prospective, Open-Label, Post-Marketing Study. Authors: Nicola Kefalas, Sofia Ruiz Del Cueto, Carola De La Guardia, Graeme Kerson, Fernando Urdiales Galvez, Alessandro Gritti
  11. An Evaluation of VYC-17.5L for the Treatment of Marionette Lines: A Prospective, Open-Label, Post-Marketing Study. Authors: Nicola Kefalas, Sofia Ruiz Del Cueto, Carola de la Guardia, Graeme Kerson, Fernando Urdiales Galvez, Alessandro Gritti
  12. Perceptions surrounding aging and aesthetic medicine later in life: Findings from a multi-country survey of adults aged 50 to 80 years with varying relationships with aesthetic medicine. Authors: Shannon Humphrey, MD; Jose Raul Montes, MD; Nancy Etcoff, PhD; Sasha Tyndale, MA; Stephanie Manson Brown, MBBS, MRCS, MFPM
  13. Aesthetic Concerns Regarding Face and Body Appearance Among Black Women: Results from A Large, Multigenerational Survey of Aesthetically-Inclined Adults in the US. Jeanine Downie, MD; Gaurav Bharti, MD; Charles Boyd, MD; Deirdre Hooper, MD; Amir Moradi, MD; Heather Woolery-Lloyd, MD; Elena Dimitrijevic, PhD; Jorge Ng Zheng, PharmD; Cheryl Burgess, MD
  14. Aesthetic concerns regarding face and body appearance among Hispanic and Latino Women: Results from Hispanic and Latino female-identifying participants of a large survey of aesthetically-inclined adults in the US. Authors: Sabrina Fabi, MD; Gaurav Bharti, MD, FACS; Charles Boyd, MD; Elena Dimitrijevic, PhD; Rosalyn George, MD; Elizabeth Houshmand, MD, FAAD; Alda Karic, PharmD; Zakia Rahman, MD, FAAD; Heather Woolery-Lloyd, MD, FAAD
  15. Aesthetic concerns regarding face and body appearance among Asian Women: Results from Asian female-identifying participants of a large survey of aesthetically-inclined adults in the US. Authors: Annie Chiu, MD; Charles Boyd, MD; Cheryl Burgess, MD; Omer Ibrahim, MD; Amir Moradi, MD; Mona Sadeghpour, MD; Noëlle Sherber, MD, FAAD; Neha Tandon, PhD; Jorge Ng Zheng, PharmD, MBA, BCMAS; Zakia Rahman, MD, FAAD
  16. Aesthetic concerns regarding face and body appearance among women: Results from white female-identifying respondents of a large survey of aesthetically inclined adults in the US. Authors: Noelle Sherber, Jeanine Downie, Sabrina Fabi, Rosalyn George, Mona Sadeghpour, Birgitte Sondergaard, Alda Karic, Deirdre Hooper
  17. Aesthetic concerns regarding face and body appearance among men: Results from male-identifying participants of a large survey of aesthetically-inclined adults in the U.S. Authors: Omer Ibrahim, MD, FAAD; Elizabeth B. Houshmand, MD, FAAD; Noëlle Sherber, MD, FAAD; Kamakshi Zeidler, MD, FACS; Raza Ahmed, MD; Jorge A. Ng Zheng, PharmD, MBA, BCMAS; Terrence Keaney, MD, FAAD

1 Allergan Aesthetics. Ethics social listening. October 2022 – REF-102346

Allergan Aesthetics (PRNewsfoto/AbbVie)



For further information: Contacts: Kate McShane, Director, Corporate Communications, Cell +1862.325.6984, Email; Karen Dennehy, International Communications & PR, Email



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?